Cleared Traditional

NeuralScan System (K192753) - FDA 510(k) Clearance

Class II Neurology device cleared through predicate-based substantial equivalence - typically does not require clinical trials.

K192753 · Medeia, Inc. · Neurology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Mar 2020
Decision
169d
Days
Class 2
Risk

K192753 is an FDA 510(k) clearance for the NeuralScan System. Classified as Full-montage Standard Electroencephalograph (product code GWQ), Class II - Special Controls.

Submitted by Medeia, Inc. (Santa Barbara, US). The FDA issued a Cleared decision on March 17, 2020 after a review of 169 days - an extended review cycle.

This device falls under the Neurology FDA review panel, regulated under 21 CFR 882.1400 - the FDA neurology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Standard predicate-based submission. Standard predicate reliance. This clearance follows a standard predicate-based equivalence path within the Neurology review framework, consistent with the majority of Class II 510(k) submissions.

View all Medeia, Inc. devices

Submission Details

510(k) Number K192753 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received September 30, 2019
Decision Date March 17, 2020
Days to Decision 169 days
Submission Type Traditional
Review Panel Neurology (NE)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
21d slower than avg
Panel avg: 148d · This submission: 169d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

Device Classification

Product Code GWQ Full-montage Standard Electroencephalograph
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 882.1400
Definition Acquire, Display, Store, And Archive Electroencephalographic Signals From The Brain Using A Full Montage Array (i.e., 16 Or More Electrodes) And User-specified Locations
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Neurology devices follow this clearance model.

Regulatory Consultant

Compliance and Regulatory Services, LLC
Daniel Lehtonen

The regulatory consultant manages the 510(k) submission process on behalf of the applicant - coordinating technical documentation, predicate strategy and FDA communications. Identifying the consultant behind a submission is a key signal for competitive regulatory intelligence.

Regulatory Peers - GWQ Full-montage Standard Electroencephalograph

All 42
Devices cleared under the same product code (GWQ) and FDA review panel - the closest regulatory comparables to K192753.
Cadwell Apollo System
K201819 · Cadwell Industries, Inc. · Sep 2020
Maxxi Position Sensor
K191492 · Neurovirtual USA, Inc. · Apr 2020
iCEWav Neuromonitoring Platform
K191868 · Ice Neurosystems, Inc. · Mar 2020
Cadwell Zenith System
K181466 · Cadwell Industries, Inc. · Sep 2018
Cadwell Apollo System
K180269 · Cadwell Industries, Inc. · Jul 2018
Natus Brain Monitor Amplifier
K180290 · Natus Medical Incorporated Dba Excel-Tech Ltd. (Xltek) · Jun 2018